Fibrocell Science, Inc., a company focused on autologous cell and gene therapy that is developing top treatments to address rare and life-threatening skin and connective tissue illnesses, has announced that it will report its first quarter 2015 results next Friday, May 8, 2015. The report will be made available to the public before the United States financial markets open. On the same day, Fibrocell will be hosting a conference call and webcast at 8:30 a.m. EDT to discuss the report, followed by a question-and-answer session. It is anticipated that the company will offer updates on progress in developing therapies to address scleroderma related diseases.
In order to participate in the live call, dial 855-877-0343 (domestic) or +1-678-509-8772 (international) and key in conference code 24959014 about 10 minutes before the start of the presentation. The conference call will also be webcast live on Fibrocell’s website at www.fibrocellscience.com/investors/events-and-presentations/. The event will be archived and available for viewing about 30 days after the call. Please access Fibrocell’s website a few minutes before the beginning of the broadcast to ensure that any needed software to view the webcast can be downloaded previously.
Azficel-T, Fibrocell’s most advanced drug candidate, addresses dysphonia by using its FDA-approved proprietary autologous fibroblast technology. The therapy is currently in a Phase II clinical trial to treat chronic dysphonia, which results from vocal cord atrophy or scarring. In partnership with Intrexon Corporation, a top firm in synthetic biology, Fibrocell is also advancing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts, and its lead therapy candidate FCX-007 is in late stage pre-clinical advancement to treat recessive dystrophic epidermolysis bullosa. A second gene therapy candidate is also being developed, FCX-013, to address scleroderma.
Read More Recent News
A new study recently published in the journal Science revealed that a specific skin cell type is associated to wound healing and scarring in mice. The study is entitled “Identification and isolation of a dermal lineage with intrinsic fibrogenic potential” and was conducted by researchers at Stanford University School of Medicine.
Fibroblasts are the main cell type responsible for collagen synthesis and the extracellular matrix of organs. Fibroblasts also have a critical role in wound healing as scars are mainly composed of collagen.
In this study, the research team hypothesized that this type of fibroblast, called “engrailed-positive fibroblasts” (EPF), could be responsible for collagen accumulation in the wound healing process and scar formation. Researchers genetically engineered mice in which EPF cells were tagged with a green fluorescent protein to allow their monitoring throughout mice development.